{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T20:45:38Z","timestamp":1776113138109,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13555-025-01446-7","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:48:05Z","timestamp":1748533685000},"page":"2275-2279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2775-8192","authenticated-orcid":false,"given":"Neenu","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7078-280X","authenticated-orcid":false,"given":"Omar","family":"Chircop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas C.","family":"Kreeshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamish J. A.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"1446_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. Br J Dermatol. 2021;184:437\u201349. https:\/\/doi.org\/10.1111\/bjd.19574.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1446_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/ICO.0000000000003162","volume":"42","author":"T Mickevicius","year":"2022","unstructured":"Mickevicius T, Pink AE, Bhogal M, Lrs C, O\u2019brart D, Robbie SJ. Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-induced adverse ocular events-incidence, etiology, and management. Cornea. 2022;42(4):507\u201319. https:\/\/doi.org\/10.1097\/ICO.0000000000003162.","journal-title":"Cornea"},{"key":"1446_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdcr.2024.01.021","volume":"46","author":"EI Herman","year":"2024","unstructured":"Herman EI, Burgy J, Shahriari M. A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients. JAAD Case Rep. 2024;46:40\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2024.01.021.","journal-title":"JAAD Case Rep"},{"key":"1446_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/cea.14305","volume":"53","author":"R Achten","year":"2023","unstructured":"Achten R, Dekkers C, Bakker D, van Luijk C, de Graaf M, van Wijk F, et al. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series. Clin Exp Allergy. 2023;53:586\u20139. https:\/\/doi.org\/10.1111\/cea.14305.","journal-title":"Clin Exp Allergy"},{"key":"1446_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s13555-024-01143-x","volume":"14","author":"T Torres","year":"2024","unstructured":"Torres T, Sohrt Petersen A, Ivens U, Bosch Vilaro A, Stinson J, Carrascosa JM. Matching-adjusted indirect comparison of the efficacy at week 32 of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis. Dermatol Ther. 2024;14:983\u201392. https:\/\/doi.org\/10.1007\/s13555-024-01143-x.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01446-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01446-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01446-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T12:48:29Z","timestamp":1752410909000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01446-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1446"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01446-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Neenu Sebastian has received funding to support conference attendance from AbbVie. Omar Chircop and Tim H Clayton have no conflicts of interest. Firas C Kreeshan has been a speaker for AbbVie, Almirall, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; received honoraria and\/or consultancy fee and\/or travel bursaries and\/or Educational grants have been from: Abbvie, Almirall, Galderma, Janssen, Leo pharma, Eli Lilly, Sanofi and UCB; and been an investigator (Sub-I) for Abbvie, Jansen and Eli Lilly. Hamish JA Hunter has received grant funding from AbbVie, Pfizer, Janssen and Merck Serono; honoraria and\/or consultancy fees and\/or travel bursaries from La Roche-Posay, Janssen, Abbvie, UCB, Sanofi Genzyme, Regeneron, Novartis, Almirall, Leo, Eli Lilly DICE Therapeutics, UNION Therapeutics, Pfizer and Galderma and has acted as an investigator for Janssen, Abbvie, UCB, Sanofi Genzyme, Novartis, Almirall, Leo, Eli Lilly, DICE Therapeutics, UNION Therapeutics, Evelo Biosciences Inc., ONO Pharmaceutical Co. Ltd. Bayer Pharmaceuticals, Artax Biopharma, Sudo Biosciences and No7 Beauty Company. Richard B Warren has acted as a consultant and\/or speaker for and\/or received research grants from AbbVie, Amgen, Almirall, Celgene, Eli Lilly, Pfizer, LEO Pharma, Novartis, Janssen Cilag, Medac, UCB Pharma and Xenoport. Richard B Warren is an Editor-in-Chief of Dermatology and Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data is captured in routine clinical care assessing the safety and efficacy of patients using a new therapy in our centre. It's standard for us to audit new therapies in this way and additional ethics is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}